Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
Jutta Gärtner(German Center for Pediatric and Adolescent Rheumatology), Ludwig Kappos(University Hospital of Basel), Roman Willi(Multiple Sclerosis Research Institute), Wendy Su(Novartis (Switzerland)), Habib Ganjgahi(University of Warwick), Jeffrey A. Cohen(Dartmouth Health), Dieter A. Häring(Novartis (Switzerland)), Amit Bar‐Or(University of Pennsylvania), Anne H. Cross(Washington University in St. Louis), Ratnakar Pingili(Novartis (France)), Bingbing Li(Novartis (France)), Stephen L. Hauser(University of California, San Francisco), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Bernd C. Kieseier(Novartis (Switzerland)), Kumaran Deiva(Sorbonne Université)
Cited by 103
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k